Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04626 (erbB-2)
 5,251 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Paraffin wax sections of 70 surgically resected colorectal adenocarcinomas were examined for the overexpression of HER2/c-erbB-2 oncoprotein using three different specific antibodies and the avidin-biotin immunoperoxidase technique. The patients included 38 men and 32 women aged between 47 and 80 years. The tumours were derived from various parts of the large intestinal tract, and represented all three stages of Dukes' classification and the three histological grades of differentiation. Many tumour sections also included adjacent normal or transitional mucosa. Eight tubular adenomas found in the colectomy specimens in association with some carcinomas were also examined. No positive membrane staining was seen in any of the 70 carcinomas, four adenomas, two hyperplastic polyps, nor in the adjacent normal or transitional mucosa. It is suggested that the overexpression of c-erbB-2 gene product is unlikely to be as common and as pronounced in colorectal adenocarcinoma as it is in ductal carcinoma of the breast.
 ...
PMID:HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. 135 6

The expression of the erbB-2 gene product was studied immunohistochemically on 38 normal colonic mucosae, 14 adenomas and 44 colon cancers, with the use of two anti-erbB-2 antibodies, a rabbit polyclonal antibody specific for the intracellular domain and a mouse monoclonal antibody specific for the extracellular domain. Normal mucosae and adenomas were not stained. Five cases (11%) of colon cancer were positive with the polyclonal anti-erbB-2 antibody, while only one case was positive with the monoclonal antibody. Most of the positive cases were in Dukes C stage. The rare overexpression of the erbB-2 protein in colon cancer seems to indicate a minor role for the gene in colorectal tumorigenesis.
 ...
PMID:erbB-2 gene expression in colorectal cancer. 198 87

To determine the frequency and clinical significance of oncogene abnormalities in colon cancer, deoxyribonucleic acids from 45 colon carcinomas and 15 benign adenomas were hybridized with 14 different protooncogene probes. Abnormalities of oncogenes were found in 22% of cancers at the time of resection. Amplification of c-myc or c-erbB-2 and allelic deletion of c-ras-Ha or c-myb were the most frequent abnormalities. The presence of altered oncogenes did not correlate with Dukes' stage, tumor progression, or patient survival after resection. One adenoma had an allelic deletion of the c-myb oncogene which was not seen in either the normal colon or an adjacent carcinoma. These data indicate that the spectrum of altered protooncogenes in colon carcinoma is similar to that of other adenocarcinomas, and that unstable oncogenes can be found before overt malignancy develops.
 ...
PMID:Protooncogene abnormalities in colon cancers and adenomatous polyps. 355 13

Expression of c-erbB-2 and p53 protein was analysed retrospectively by immunohistochemistry in formalin-fixed tissue samples from 293 patients with colorectal adenocarcinoma. There was a significant positive relationship between c-erbB-2 and p53 expression (P < 0.0001). Co-overexpression of c-erbB-2 and p53 tended to be increased in tumours with infiltrative growth (P = 0.08) and higher S-phase fraction (P = 0.085). In combined survival analysis, patients with tumours in both c-erbB-2 positivity and p53 negativity had a more favourable outcome (P = 0.03). Multivariate analysis revealed that p53 overexpression was significantly associated with poor prognosis independent of c-erbB-2 expression, DNA-ploidy, S-phase fraction, growth pattern and Dukes stage (P = 0.002). We conclude that there is an inter-reaction between the two oncoproteins in the tumour development and that the overexpression of p53 proteins may be a powerful prognostic predictor in colorectal adenocarcinoma.
 ...
PMID:Expression of c-erbB-2 and p53 in colorectal adenocarcinoma. 754 94

Mutant p53 tumour suppressor gene and c-erbB-2 proto-oncogene are involved in human carcinogenesis, and their protein product detection in human malignancies might influence the evolution of many neoplasms. Our aim was to estimate their association with histopathological and clinical parameters of prognostic value in colorectal cancer. An immunohistochemical assay was undertaken in formalin-fixed sections from tissue specimens of 60 colorectal carcinomas. Nuclear p53 expression was detected in 46.6%, while membranic c-erbB-2 positivity was noticed in 35% of the examined cases. P53 positivity rate significantly correlated with poor differentiation (p < 0.001), high mitotic activity (p < 0.0001), tumour stage (p < 0.001) and 5-year overall survival period (p < 0.01). C-erbB-2 positivity incidence significantly correlated with advanced Dukes' stage (p < 0.001) and high mitotic activity (p < 0.05). Significant association between p53 and c-erbB-2 immunostaining was observed (p < 0.05) and p53/c-erbB-2 co-expression was related to poor differentiation (p < 0.001), high mitotic activity (p < 0.001), advanced Dukes' stage (p < 0.001), tumour aneuploidy (p < 0.05) and worse overall survival (p < 0.05). P53 and c-erbB-2 immunohistochemical detection in combination with known prognostic indicators may be a useful future tool in determining colorectal cancer prognosis and subsequently in deciding on optimal postoperative treatments.
 ...
PMID:Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. 757 15

Overexpression of the c-erbB-2 oncogene has been demonstrated in a variety of tumours, including colorectal tumours. In breast carcinoma, c-erbB-2 overexpression is associated with DNA ploidy, some other prognostic indicators, and unfavourable survival prospects. However, there is little such information available regarding colorectal tumours. In this study, c-erbB-2 was analysed retrospectively by immunohistochemistry in 293 primary colorectal adenocarcinomas to assess its relation to DNA ploidy, S-phase fraction, other prognostic factors, and patient survival. Using the monoclonal antibody NCL-CB11, we found that 23% of the tumours were strongly c-erbB-2 positive, while 36% showed weak expression. The highest frequency of c-erbB-2 expression was 81% in DNA tetraploid tumours, compared to 63% in aneuploid and, 53% in diploid tumours (test for heterogeneity, p = 0.031). Overexpression of c-erbB-2 indicated a favourable prognosis in patients with DNA aneuploid tumours (p = 0.0088), but not in those with diploid or tetraploid tumours. The prognostic value of c-erbB-2 in DNA aneuploid tumours remained even after adjustment for Dukes' stage (p = 0.027). The results suggest that a combination of c-erbB-2 expression and DNA ploidy may improve the identification of patients' risk of cancer death.
 ...
PMID:c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. 761 63

The prognostic significance of c-erbB-2 expression was studied in paraffin wax embedded colorectal cancer tissue using a monoclonal antibody. One hundred and sixty-four patients with Dukes' B disease were studied. Membranous staining was not detected in any case. Cytoplasmic c-erbB-2 staining was seen in 55 cancers (33.5%). Cytoplasmic staining was unrelated to patient age (P = 0.31), sex (P = 0.69), tumour site (P = 0.69), size (P = 0.57), histological grade (P = 0.42) or ploidy status (P = 0.21) but was found more frequently in obstructing cancers (P = 0.03). Mean follow up of the patient population was 6.3 years. Five-year-survival estimated by the Kaplan-Meier life-table method was 47% for those with cytoplasmic c-erbB-2 staining and 77% for those without (log rank analysis; P < or = 0.0001). Stepwise regression analysis identified c-erbB-2 staining (relative risk, 2.51; P = 0.0005) and bowel obstruction (relative risk, 1.99; P = 0.015) as independent predictors of survival. It is suggested that cytoplasmic c-erbB-2 expression may provide a useful marker of tumour behaviour in Dukes' B colorectal cancer.
 ...
PMID:Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. 786 86

Correlation of c-erbB-2 protein (n = 44), epidermal growth factor receptor (EGFR) (n = 41) expression, and DNA ploidy pattern (n = 42) with clinical outcomes of human colorectal cancers was studied. Using monoclonal antibodies against c-erbB-2 protein and EGFR, an immunohistochemical study of the expression of c-erbB-2 protein and EGFR in frozen tissue sections from the lesion was performed. There was no significant correlation between the expression of c-erbB-2 protein and clinicopathological findings such as, tumor size, histological type, depth of invasion, lymph node metastasis, lymphatic vessel invasion, or venous invasion. However, the incidence of c-erbB-2 protein expression in Dukes D was significantly higher (9/10, 90%) than that in Dukes A to C (16/34, 47.1%). Similar tendency was also observed in the expression of EGFR. Aneuploid case was observed in 12 of observed 25 (48%) cases without lymph node metastasis, while it was observed in 16 of 17 cases (94.1%) with lymph node metastasis and there was significant association between DNA ploidy pattern and lymph node metastasis (P < 0.01) and most of the cases (17/20, 85%) were aneuploidy in Dukes C and D. The results above suggest that the expression of c-erbB-2 protein or EGFR was associated with distant metastasis, while on the other hand DNA ploidy pattern was correlated with lymph node metastasis.
 ...
PMID:Study of c-erbB-2 protein and epidermal growth factor receptor expression and DNA ploidy pattern in colorectal carcinoma. 790 86

The coexpression of EGFR and c-erbB-2 protein was examined immunohistochemically in a total of 62 freshly frozen specimens of colorectal cancer, and correlations between the coexpression of both receptors and their clinicopathological variables were analyzed. Positive staining of both receptors was found in 21 cases, and it was related to the degree of lymphatic or vascular invasion of cancer cell, the synchronous metastasis to liver or lung, and the most advanced stage (Dukes' D). Moreover, the incidence of the distant metastasis including metachronous metastasis to other organs such as liver, lung or peritoneum were significantly higher in the positive cases of both receptors. These results suggest that the coexpression of EGFR and c-erbB-2 protein may be related to the distant metastasis of colorectal cancer.
 ...
PMID:[Immunohistochemical study of the coexpression of epidermal growth factor receptor (EGFR) and c-erbB-2 protein in colorectal cancer]. 790 10

Sections of normal colon, adenomas, and adenocarcinomas were examined by immunohistochemistry for the expression of c-erbB-2 proto-oncogene product in order to assess its potential diagnostic value in predicting the malignant potential of these lesions. We compared the degree of epithelial abnormality and clinical parameters, including Dukes' classification and survival time with the extent of immunoperoxidase staining. Sections of normal colon and tubular adenomas examined demonstrated a weak immunostaining localized to the luminal surface cells. However, higher level of c-erbB-2 expression was observed in dysplastic areas of one tubular and one villous adenoma. Out of 40 adenocarcinomas, only 2 samples showed weak immunoreaction, while 38 samples were moderately or strongly positive for c-erbB-2 protein. The intensity of staining correlated positively with the stage of disease and postoperative survival time.
 ...
PMID:High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters. 791 91


1 2 Next >>